Lantern Pharma is expected to report a Q2 2026 loss of $0.38 per share on $0 revenue, with its current stock price of $2.88 significantly trailing the average analyst target of $18.00.
Investors are primarily focused on the progress of the Phase 2 HARMONIC trial, specifically for patients with the EGFR L858R mutation, and the initial commercial traction of the withZeta.ai platform.
The company recently demonstrated a 47% reduction in R&D spend through AI-driven efficiencies while successfully raising $9.25 million in new financing. Management's updated guidance on the cash runway, currently projected into early 2027, will be critical for sustaining its expanding clinical pipeline in India and the U.S.